GeoVax Labs Explores Needle-Free Vaccine Delivery with Vaxxas' HD-MAP Technology

GeoVax Labs, Inc. has initiated a research program to evaluate the immunogenicity and stability of its GEO-MVA vaccine when delivered via Vaxxas' high-density microarray patch (HD-MAP) technology. This innovative approach, currently under study at the University of Queensland, seeks to establish a needle-free, self-administered vaccine platform that could transform pandemic preparedness and immunization strategies worldwide.

The HD-MAP technology offers numerous benefits compared to conventional vaccine delivery methods, such as the possibility for self-administration, higher patient acceptance, and enhanced thermostability. These advantages could drastically decrease the need for cold chain storage and remove the hazards linked with needle use, thereby improving vaccine accessibility in low- and middle-income countries.

David Dodd, Chairman and CEO of GeoVax, emphasized the program's capacity to address the global demand for more accessible and efficient vaccines. A successful outcome from this study could lead to the development of a thermostable, needle-free GEO-MVA vaccine, ideal for pandemic response, biodefense stockpiling, and standard immunization programs.

The Vaxxas HD-MAP platform has previously demonstrated its ability to boost immunogenicity in various research studies. Furthermore, GeoVax's recent positive scientific feedback from the European Medicines Agency suggests a smoother regulatory process for GEO-MVA, potentially accelerating its development and approval as an additional Mpox vaccine candidate in the EU. For more information on GeoVax's initiatives, visit https://www.geovax.com.